Caladrius Biosciences (CLBS) Downgraded by Zacks Investment Research to Hold

Caladrius Biosciences (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $18.50 target price on shares of Caladrius Biosciences in a report on Thursday, January 24th.

Caladrius Biosciences stock traded up $0.02 on Monday, hitting $5.25. The company’s stock had a trading volume of 17,100 shares, compared to its average volume of 22,086. The firm has a market capitalization of $51.47 million, a PE ratio of -2.95 and a beta of 1.89. Caladrius Biosciences has a one year low of $3.05 and a one year high of $11.65.

Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.20. As a group, sell-side analysts forecast that Caladrius Biosciences will post -1.75 EPS for the current year.

An institutional investor recently raised its position in Caladrius Biosciences stock. Renaissance Technologies LLC lifted its position in Caladrius Biosciences Inc (NASDAQ:CLBS) by 42.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 280,864 shares of the biotechnology company’s stock after purchasing an additional 84,301 shares during the quarter. Renaissance Technologies LLC owned 2.85% of Caladrius Biosciences worth $1,657,000 at the end of the most recent reporting period. Institutional investors own 7.73% of the company’s stock.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Featured Story: Outstanding Shares

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit